Quoin Pharmaceuticals Ltd. - American Depositary Receipt (QNRX)
Summary
QNRX Chart
Quoin Pharmaceuticals Ltd. - American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Matthew Okkerse Dauntless Investment Group LLC | 196,592 | $1.3M | $815,856.8 | -$481,650.2 | -37.12% |
 SummitTX Capital LP SummitTX Capital LP | 100,300 | $1.17M | $411,230 | -$758,095 | -64.83% |
Quoin Pharmaceuticals Ltd. - American Depositary Receipt Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Aydin Huseynov Ladenburg Thalmann | -7.33 | $867,484.28 | $32.61 | $867,451.67 | 100% |
Quoin Pharmaceuticals Ltd. - American Depositary Receipt (QNRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Quoin Pharmaceuticals Ltd. - American Depositary Receipt ever had a stock split?
Quoin Pharmaceuticals Ltd. - American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Michael Myers CEO | NASDAQ (CM) Exchange | 74907L409 CUSIP |
| US Country | 4 Employees | 23 Oct 2019 Last Dividend | 9 Apr 2025 Last Split | 29 Jul 2016 IPO Date |
Overview
Quoin Pharmaceuticals, Ltd. is a clinical stage specialty pharmaceutical company that is dedicated to the development and commercialization of therapeutic products targeting rare and orphan diseases. Founded in 2018 and headquartered in Ashburn, Virginia, Quoin Pharmaceuticals is making significant strides in addressing unmet medical needs. The company establishes its strength through strategic partnerships and agreements which include a license agreement with Skinvisible Inc., consulting agreements with Axella Research LLC, a Master Service Agreement with Therapeutics Inc., and a research agreement with Queensland University of Technology.
Products and Services
-
QRX003
A topical lotion under development aimed at treating Netherton Syndrome (NS), a rare genetic skin condition. This lead product demonstrates Quoin Pharmaceuticals' focus on innovative and targeted therapies.
-
QRX004
Another pioneering product in development, QRX004, is focused on treating recessive dystrophic epidermolysis bullosa, a debilitating skin disorder characterized by the skin becoming very fragile and forming severe blisters.
-
QRX007
A therapeutic product also targeting Netherton Syndrome (NS), QRX007 showcases the company's dedicated efforts to offer multiple solutions for rare diseases, emphasizing its commitment to patients suffering from NS.
-
QRX008
Designed for the treatment of scleroderma, an autoimmune disease that causes hardening and tightening of the skin and connective tissues, QRX008 reflects Quoin Pharmaceuticals' strategy to diversify its portfolio to cover a wide range of rare diseases.
